164 related articles for article (PubMed ID: 36609207)
1. Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Milani A; Tuninetti V; Pignata S; Lorusso D; Castaldo D; De Giorgi U; Savarese A; Biglia N; Scandurra G; Mangili G; Di Maio M; Turinetto M; Bellero M; Mammoliti S; Testa S; Scotto G; Purro A; Artioli G; Valabrega G
Tumori; 2023 Oct; 109(5):490-495. PubMed ID: 36609207
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
Schaefer JK; Li M; Wu Z; Basu T; Dorsch MP; Barnes GD; Carrier M; Griggs JJ; Sood SL
J Thromb Haemost; 2021 Jan; 19(1):212-220. PubMed ID: 33104289
[TBL] [Abstract][Full Text] [Related]
4. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi B
Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
[No Abstract] [Full Text] [Related]
5. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada.
Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ
Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
Klamroth R; Sinn M; Pollich C; Bischoff S; Lohneis A; Orlovic AM; Wisłocka L; Habbel P; de Wit M; Späth-Schwalbe E; Scholz CW; Riess H
Oncol Res Treat; 2022; 45(4):178-185. PubMed ID: 34963120
[TBL] [Abstract][Full Text] [Related]
7. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
Swartz AW; Drappatz J
Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
[TBL] [Abstract][Full Text] [Related]
10. Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants.
Kim SA; Yhim HY; Bang SM
J Korean Med Sci; 2019 Feb; 34(6):e52. PubMed ID: 30787683
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism.
Matzdorff A; Langer F
Hamostaseologie; 2020 Dec; 40(5):655-661. PubMed ID: 32356293
[TBL] [Abstract][Full Text] [Related]
12. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
[TBL] [Abstract][Full Text] [Related]
13. Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis.
Attard LM; Gatt A; Bertoletti L; Delluc A; Riva N
Vasc Health Risk Manag; 2022; 18():793-807. PubMed ID: 36268462
[TBL] [Abstract][Full Text] [Related]
14. Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States.
Guo JD; Hlavacek P; Poretta T; Wygant G; Lane D; Gorritz M; Wang X; Chen CC; Wade RL; Pan X; Rajpura J; Stwalley B; Rosenblatt L
J Thromb Thrombolysis; 2020 Aug; 50(2):386-394. PubMed ID: 31955338
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology.
Scanlon LR; Khaksari B; Goel S; Nevadunsky NS; Wright JD; Gressel GM
Gynecol Oncol; 2023 Jun; 173():68-73. PubMed ID: 37105059
[TBL] [Abstract][Full Text] [Related]
17. The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants.
Prandoni P
Expert Opin Pharmacother; 2015; 16(16):2391-4. PubMed ID: 26360919
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
[TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
20. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]